Ruthigen Inc. (RTGN) 5.06 $RTGN A Dozen Reasons To Love

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ruthigen Inc. (RTGN) 5.06 $RTGN

A Dozen Reasons To Love Dermatology Companies
ACCESSWIRE - Tue Jul 14, 8:25AM CDT
WHITEFISH, MT / ACCESSWIRE / July 14, 2015 / There are a number of reasons investors worldwide love dermatology companies. For starters, support of innovation has been key in gaining a far better understanding of skin conditions and advancing effective, safe therapies capable of becoming standards of care. Of course, Wall Street loves upside potential. At a more granular level, the logic underscoring dermatology as a good investment is quite diverse. As David M. Steinberg, Managing Director Equity Research at Jeffries, puts it, dermatology products have several general attributes: 1) shorter development timelines; 2) lower clinical trial costs; 3) perceived lower regulatory hurdles; 4) high cash pay components for aesthetics; 5) a recent track record of success; and 6) a really active M&A market, which Mr. Steinberg described as a second way for shareholders to win. Oculus Innovative Sciences' (NASDAQ: OCLS) CFO Bob Miller and CEO Jim Schutz expanded on Steinberg's view in the company's June earnings call, adding 7) derm has strong pricing, product margins, and insurance coverage; 8) it is a concentrated call point, meaning companies don't need an enormous sales force to cover; 9) derm has fast sales ramps; and 10) dermatology has great valuations or multiples on revenue.
VRX: 29.12 (+0.09), DERM: 32.22 (+1.18), ANAC: 99.06 (-0.14), RTGN: 5.06 (+1.01), OCLS: 4.13 (+0.04), NVS: 78.27 (-0.50)

Oculus Innovative Sciences Announces Sale of 1.65 Million Shares of Ruthigen Stock for $4.5 Million in Non-Dilutive Funding
GlobeNewswire - Tue Jun 16, 5:00AM CDT
-- Ruthigen/Pulmatrix merger closed on June 15, 2015, enabling Oculus' sale of Ruthigen shares to close on or before June 18, 2015
OCLSW: 0.23 (-0.01), RTGN: 5.06 (+1.01), OCLS: 4.13 (+0.04)

These Biotech Stocks Could Deliver Big Returns for Investors
ACCESSWIRE - Mon Jun 15, 8:35AM CDT
NEW YORK, NY / ACCESSWIRE / June 15, 2015 / This week's events will be focused on the ongoing Greece negotiations with creditors, the largest among them being the IMF, the ECB and Germany. Additionally the FOMC minutes will be released this week pointing investors to clues as to whether the Fed is still patient regarding the proposed first rate hike. Our opinion at UltimateStockAlerts.com has been consistent on this topic for over 3 years now:
IDRA: 1.92 (+0.01), SNSS: 0.80 (-0.01), RTGN: 5.06 (+1.01), XOMA: 0.56 (-0.01)

Oculus Beats Consensus Sales Expectations by 30 Percent, Turnaround Plan Working
ACCESSWIRE - Mon Jun 15, 8:28AM CDT
WHITEFISH, MT / ACCESSWIRE / June 15, 2015 / At the end of May, shares of Oculus Innovative Sciences (NASDAQ: OCLS) broke above their 50 day moving average, a technical resistance at 90 cents and another at $1.05. The move continued to fill a previously open gap at $1.08 and take shares above their 200 day moving average, a sign of bullishness in technical analysis, as the stock printed as high as $1.97 on Tuesday. From the May low of 65 cents, the stock made a bottom-to-top move of 203%. All of this upward movement is important, as the company has received a delisting notice from NASDAQ for deficient bid price. The stock needs to close above $1 for 10 consecutive days in order to satisfy NASDAQ requirements for continued listing. Through June 12, the closing price was above $1 for eight consecutive days.
RTGN: 5.06 (+1.01), OCLS: 4.13 (+0.04)

Ruthigen and Pulmatrix Stockholders Approve Merger
PR Newswire - Fri Jun 12, 3:01PM CDT
Ruthigen, Inc. ("Ruthigen" (NASDAQ: RTGN) and Pulmatrix Inc. ("Pulmatrix" today announced that at Ruthigen's special meeting of stockholders held on June 12, 2015, Ruthigen obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Ruthigen and Pulmatrix. Pulmatrix previously obtained a sufficient number of written consents from its stockholders to consummate the merger.
RTGN: 5.06 (+1.01)

Panning for Golden Stocks Outside the Gold Industry
ACCESSWIRE - Thu May 28, 4:51PM CDT
WHITEFISH, MT / ACCESSWIRE / May 28, 2015 / Gold miners are their own special breed, utilizing skills most laymen do not understand to analyze the ground, drilling to confirm targets and digging-in to unearth the precious yellow metal. Throughout the world, though, there are still plenty of artisanal miners finding gold and others plucking a nugget from a pan that they stuck in a stream. Whatever the method, it often takes poring through plenty of material and some savvy vision to find the payoff, a tactic that can be applied to many applications in life, including the stock market.
ABT: 42.30 (+0.28), PHG: 29.31 (+0.37), PDCO: 46.03 (+0.03), RTGN: 5.06 (+1.01), OCLS: 4.13 (+0.04), NBY: 3.44 (+0.04)

Antifungals, an Overlooked Biotech Niche With Big Potential
ACCESSWIRE - Wed May 20, 7:37AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 20, 2015 / If a global competition were held for the planet's most sadly ironic places, the hospital would place very high, if not win outright. This is not only true from before the late 19th century when the germ theory of disease became widely accepted. Before then, the hospital - a place that is designed to heal the sick - was just about the best place on Earth to contract a life-threatening infection due to unsanitary surgical procedures. This is still sadly true today as well. Hospitals are still the largest breeding grounds for deadly superbug infections due to the very sanitation procedures meant to stop them.
CDTX: 11.11 (-0.46), RTGN: 5.06 (+1.01)

IPOs & Transactions Week in Review: April 13 - 17 / plus video: M&A expert panel answer 12 questions
PR Newswire - Mon Apr 20, 10:50AM CDT
Vintage, the capital markets, corporate services and institutional & fund services division of PR Newswire, has released its weekly IPO and Transaction summary.
SFBS: 52.41 (unch), RTGN: 5.06 (+1.01)

Ruthigen-Pulmatrix Merge, Focus on Respiratory Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 17, 5:33PM CDT
Ruthigen, Inc. (RTGN) and Pulmatrix entered into a definitive merger agreement upon the closing of which Pulmatrix will become a wholly-owned subsidiary of Ruthigen.
CYTK: 10.50 (-1.57), LCI: 33.37 (-0.49), SLXP: 172.96 (+0.15), RTGN: 5.06 (+1.01)

Ruthigen and Pulmatrix Enter into Merger Agreement
PR Newswire - Mon Mar 16, 6:00AM CDT
Ruthigen, Inc. (NASDAQ: RTGN), a biopharmaceutical company ("Ruthigen", and Pulmatrix, Inc., a Lexington, Massachusetts based clinical stage biotechnology company ("Pulmatrix", announced today that on March 13, 2015, they have entered into a definitive merger agreement. Upon the closing of the transactions contemplated by the merger agreement, Pulmatrix will become a wholly-owned subsidiary of Ruthigen and all of Pulmatrix's debt and equity securities outstanding prior to the consummation of the merger will be exchanged for shares of Ruthigen common stock that will represent approximately 81% of the outstanding common stock of Ruthigen. In connection with Pulmatrix's entry into the merger agreement, certain existing institutional investors in Pulmatrix entered into stock purchase agreements with Pulmatrix to invest an additional $10,000,000 in Pulmatrix upon the closing of the merger. Pulmatrix also raised approximately $4,500,000 in February 2015, in contemplation of entering into the merger agreement.
RTGN: 5.06 (+1.01)

Oculus Innovative Sciences sells 350,000 Ruthigen stock at USD2.75 per share in USD962,500 non-dilutive funding
M2 - Mon Mar 16, 4:32AM CDT
Pharmaceutical company Oculus Innovative Sciences (NASDAQ:OCLS) reported on Friday the sale of 350,000 shares of Ruthigen (Nasdaq:RTGN) stock to an undisclosed investor group at USD2.75 per share for non-dilutive funding of USD962,500.
RTGN: 5.06 (+1.01), OCLS: 4.13 (+0.04)

Oculus Innovative Sciences Announces Sale of 350,000 Shares of Ruthigen Stock for $962,500 in Non-Dilutive Funding
GlobeNewswire - Mon Mar 16, 2:05AM CDT
-- Additional $4.5 million in non-dilutive funding in sale of remaining 1.65 million Ruthigen shares upon closing of Ruthigen/Pulmatrix merger expected by no later than August 2015
RTGN: 5.06 (+1.01), OCLS: 4.13 (+0.04)

Oculus Innovative Sciences Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Thu Feb 12, 3:09PM CST
-- Total revenue of $3.2 million for the third quarter
RTGN: 5.06 (+1.01), OCLS: 4.13 (+0.04)

Oculus Innovative Sciences to divest Ruthigen shares for USD5.5m in event of Ruthigen merger
M2 - Mon Jan 12, 6:53AM CST
Pharmaceutical company Oculus Innovative Sciences (NasdaqCM:OCLS) reported on Monday the launch of a securities purchase agreement with two current Ruthigen investors.
RTGN: 5.06 (+1.01), OCLS: 4.13 (+0.04)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 10

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Antonio Filosa Takes the Helm as CEO of Stellantis N.V.

Updated Category News Views 335

Antonio Filosa Appointed as Stellantis N.V. Chief Executive Officer Stellantis N.V., a prominent player in the global automotive arena, has officially announced the appointment of Antonio Filosa as its new Chief Executive Officer. Filosa, who has amassed over 25 years of experience within the automotive sector, currently holds the position of Chief Operating Officer for...

Continue Reading
Understanding the Edwards Lifesciences Legal Landscape

Updated Category News Views 278

Understanding Recent Legal Issues for Investors In the world of investment, understanding legal implications can often feel overwhelming, especially when a company faces a class action lawsuit. Edwards Lifesciences Corporation, a name recognized for its innovative heart valve technologies, currently finds itself embroiled in legal battles that could shape its future and...

Continue Reading
Arrive Home and FormFree Join Forces to Enhance Homeownership Access

Updated Category News Views 155

Arrive Home Partners with FormFree for Innovative Solutions The innovative collaboration between Arrive Home and FormFree aims to transform the landscape of homeownership for many borrowers facing challenges due to limited credit histories. This partnership is particularly significant as it opens doors for those who have previously been overlooked by traditional credit...

Continue Reading
Verizon's $20 Billion Acquisition: A Strategic Expansion Ahead

Updated Category News Views 76

Verizon Announces Major Acquisition of Frontier Communications Verizon has recently made headlines by announcing a significant acquisition deal with Frontier Communications. This all-cash transaction, valued at $20 billion, underscores Verizon's dedication to substantially expanding its fiber network. Details of the Acquisition According to the proposed terms, Verizon...

Continue Reading
MoxiWorks Enhances Innovation Timeline with New Leadership and Funding

Updated Category News Views 174

MoxiWorks Enhances Innovation Timeline with New Leadership and Funding Funding from private equity and brokerage partners, along with new leadership, is set to transform MoxiWorks, a leading provider of sales and marketing software in the real estate sector. With substantial capital secured from its ownership group, which includes Vector Capital, Howard Hanna Real Estate...

Continue Reading